Zhongsheng Beikong Biotechnology (08247.HK) has been increased by approximately 4.3 million shares of the company's domestic capital stocks by its major shareholder Chen Peng.

China Life Economic APP News, Zhongsheng Beikong Biotechnology (08247.HK) announced that from June 15 to July 14, 2026, Mr. Chen Peng, the chairman, president, executive director, and major shareholder of the company, through Jingning Guo Science and Technology Kangyi Enterprise Management Center (Limited Partnership) and Guoke Health Institute Innovation Research Institute (Hefei) Partnership Enterprise (Limited Partnership), with a total cost of about RMB 10.53 million (purchase price ranging from RMB 2.40 to RMB 2.50 per share), successively acquired a total of approximately 4.30 million shares of the company's internal equity, accounting for approximately 2.97% of the total number of shares issued by the company.